HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)

Phase 4

Terminated

Brief Summary: This research study is a Phase IV clinical trial. Phase IV trials are used to further test and monitor the safety of a drug approved by the FDA and to see if the drug has any other indications that can be used to treat different diseases.

Sorafenib is a new drug, which is approved under the brand name Nexavar for the treatment of liver cancer. It is also currently being tested in various other cancers. Sorafenib works by slowing down and/or stopping the development of new cancer cells and new blood vessels. By slowing down and/or stopping the growth of new blood vessels around a tumor, it is believed that sorafenib prevents or slows down the growth of tumors.

The researchers of this study would like to study the effects of sorafenib on hepatitis C by drawing additional research blood samples from people infected with hepatitis C who are receiving sorafenib treatment for liver cancer. These tests will measure certain proteins in the blood (HCV-RNA) which may indicate if sorafenib has any effect on the hepatitis C virus.

Detailed Description: This is a prospective, open-label, non-interventional trial to evaluate HCV-RNA levels during treatment with Sorafenib in patients with advanced hepatocellular carcinoma.

Participants will receive Sorafenib 400mg orally twice daily. HCV-RNA (Hepatitis C Virus - Ribonucleic Acid) levels will be measured at baseline, week 2 of sorafenib, week 4 of sorafenib, week 6 of sorafenib, week 8 of sorafenib, week 12 of sorafenib, and 2 weeks after discontinuing sorafenib. HCV-RNA levels will be measured by drawing about 2 tablespoons of blood

During the study period, tumor assessments will be done by MRI (magnetic resonance imaging) or CT (computed tomography) scans at baseline and every 8 weeks.

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

Pregnant or breastfeeding
Undetectable HCV RNA
Uncontrolled hypertension
Active or clinically significant cardiac disease
Thrombolic, embolic, venous or arterial events within 6 months of informed consent
Pulmonary hemorrhage/bleeding event (NCI-CTCAE grade 2 or higher) within 4 weeks before study entry
Previously untreated or concurrent cancer except cervical cancer in situ, treated basal cell carcinoma or superficial bladder tumor
Presence of non-healing wound, ulcer or bone fracture
History of organ allograft
Known or suspected allergy or hypersensitivity to any of the study drugs
Any malabsorption condition
Inability to comply with the protocol and/or not willing or not available for follow up
Major surgery within 30 days prior to start of study drug

Arm && Interventions

Group	Intervention	Description
Treatment Arm	Sorafenib	Sorafenib taken orally twice per day

Primary Outcome Measures

Name	Time	Method
Decline in HCV-RNA Level	up to 2 years	Successful decline in HCV (hepatitis C virus)-RNA level, with success defined as a decrease of at least two logs of HCV-RNA between baseline and any subsequent measurement.

Secondary Outcome Measures

Name	Time	Method
Time to Radiological Tumor Progression	2 years	Time to radiological tumor progression is defined as the time period between enrollment and the earlier of tumor progression and death. Participants who are alive and progression-free at the date of last contact will be censored at this date.
Overall Survival	2 years	Overall survival is defined as the time period between enrollment and the date of death. Participants who are still alive at last contact will be censored at this date.

Locations (3): Massachusetts General Hospital
🇺🇸
Boston, Massachusetts, United States
Brigham and Women's Hospital
🇺🇸
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
🇺🇸
Boston, Massachusetts, United States